Catalyst Calendar

Thu, Jun 11, 2026

1 updates

4:05 PM

Kyntra Bio Presents New Roxadustat Data on Improvements in Transfusion Independence Regardless of Ring Sideroblast Status in Patients with Anemia due to Lower-Risk Myelodysplastic Syndromes

In a post hoc analysis, patients treated with roxadustat showed a durable and clinically meaningful improvement in transfusion independence (TI) in patients with LR-MDS and high transfusion burden (HTB) compared to placebo Similar rates of TI for patients treated with roxadustat were observed in

Presentation / Abstract • Phase 3Poster presentation Fri, Jun 12, 2026, 6:45 PM CESTkyntrabio.com

Mon, May 11, 2026

1 updates

KYNB

4:05 PM

Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46, in metastatic castration-resistant prostate cancer (mCRPC) is progressing well with the interim analysis anticipated in 4Q 2026 Positive results from the investigator-sponsored study of

kyntrabio.com

Mon, May 4, 2026

1 updates

KYNB

4:05 PM

Kyntra Bio to Report First Quarter 2026 Financial Results

SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results on Monday, May 11 after market close. Kyntra Bio will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail

kyntrabio.com